Showing 2291-2300 of 3039 results for "".
- Marinomed Biotech Reports Promising Phase 2 Results for Tacrosolv Eye Drops in Treating Allergic Rhinoconjunctivitishttps://modernod.com/news/marinomed-biotech-reports-promising-phase-2-results-for-tacrosolv-eye-drops-in-treating-allergic-rhinoconjunctivitis/2482473/Marinomed Biotech has announced clinical data from its phase 2 dose-finding clinical trial on Tacrosolv, a novel eye drop formulation for treating allergic rhinoconjunctivitis. The results, now published in the peer-reviewed journal Clinical Ophthalmology, indicate that Tacrosolv, formulated usin
- Cure Blindness Project Unveils Global Expansion Plan on World Sight Dayhttps://modernod.com/news/cure-blindness-project-unveils-global-expansion-plan-on-world-sight-day/2482471/In honor of World Sight Day on October 10, the non-profit Cure Blindness Project announced an expansion plan that will extend its sight-restoring services to six new countries: Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia. This move marks the organi
- Neuro-Optometric Rehabilitation Association Appoints Barbara Barclay as New Executive Directorhttps://modernod.com/news/neuro-optometric-rehabilitation-association-appoints-barbara-barclay-as-new-executive-director/2482455/The Neuro-Optometric Rehabilitation Association, International (NORA), has announced the appointment of Barbara Barclay as its new executive director, effective October 1. Ms. Barclay, an expert in eye-tracking technology and health tech, brings more than 30 years of leadership experience, i
- Nicox and Glaukos Sign Global Licensing Deal for Glaucoma Drug Candidatehttps://modernod.com/news/nicox-and-glaukos-sign-global-licensing-deal-for-glaucoma-drug-candidate/2482451/Nicox has entered into an exclusive research and license option agreement with Glaukos for NCX 1728, Nicox’s novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. The collaboration aims to accelerate research and development efforts for glaucoma and other serious ophth
- Viridian Announces Positive Topline Results from Phase 3 Trial of Veligrotug for TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/Viridian Therapeutics announced positive topline data from its THRIVE phase 3 clinical trial of VRDN-001, now branded as veligrotug, in patients with active thyroid eye disease (TED). Veligrotug, an intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, demo
- BVI Introduces Serenity and Serenity Toric IOLshttps://modernod.com/news/bvi-to-unveil-serenity-and-serenity-toric-premium-monofocal-iols-at-escrs/2482420/BVI has introduced the Serenity and Serenity Toric premium monofocal IOLs, which it plans to launch in Europe at the upcoming ESCRS congress in Barcelona. These non-diffractive, aspheric IOLs represent the second generation of BVI’s Isopure family, launched in 2019
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Visionix Unveils the VX 610 Automated Fundus Camerahttps://modernod.com/news/visionix-unveils-the-vx-610-automated-fundus-camera/2482407/Visionix USA announced the launch of the VX 610 non-mydriatic automated fundus camera. The VX 610 boasts a range of automated features, including auto alignment, auto focus, and auto capture. This level of automation not only streamlines the imaging process but also redu
- Lensar's ALLY Adaptive Cataract Treatment System Approved in Europehttps://modernod.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/Lensar announced that the ALLY Adaptive Cataract Treatment System is now commercially available in Europe after receiving certification under the European Union’s Medical Device Regulation (MDR). Lensar is commercializing ALLY through its di
- Topcon Launches IS-6500 Ophthalmic Instrument Standhttps://modernod.com/news/topcons-is-6500-ophthalmic-instrument-stand-launched/2482381/Topcon Healthcare announced the launch of the IS-6500 digital instrument stand in the United States, Latin America, and Canada. The IS-6500 stand joins Topcon’s portfolio of ergonomic devices for eye exams. According to the company, the IS-6500 stand incorporates specialized